Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Genet Metab ; 115(1): 48-52, 2015 May.
Article in English | MEDLINE | ID: mdl-25796965

ABSTRACT

Metachromatic Leukodystrophy (MLD; MIM# 250100) is a rare inherited lysosomal storage disorder caused by the deficiency of Arylsulfatase A (ARSA). The enzymatic defect results in the accumulation of the ARSA substrate that is particularly relevant in myelin forming cells and leads to progressive dysmyelination and dysfunction of the central and peripheral nervous system. Sulfatide accumulation has also been reported in various visceral organs, although little is known about the potential clinical consequences of such accumulation. Different forms of MLD-associated gallbladder disease have been described, and there is one reported case of an MLD patient presenting with functional consequences of sulfatide accumulation in the kidney. Here we describe a wide cohort of MLD patients in whom a tendency to sub-clinical metabolic acidosis was observed. Furthermore in some of them we report episodes of metabolic acidosis of different grades of severity developed in acute clinical conditions of various origin. Importantly, we finally show how a careful acid-base balance monitoring and prompt correction of imbalances might prevent severe consequences of acidosis.


Subject(s)
Acidosis/complications , Leukodystrophy, Metachromatic/complications , Leukodystrophy, Metachromatic/metabolism , Monitoring, Physiologic , Acid-Base Equilibrium , Acid-Base Imbalance , Acidosis/blood , Acidosis/prevention & control , Acidosis/urine , Child , Child, Preschool , Cohort Studies , Follow-Up Studies , Genotype , Humans , Infant , Retrospective Studies , Time Factors
2.
Gene Ther ; 22(6): 496-502, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25762283

ABSTRACT

Gene therapy using viral vectors that stably integrate into ex vivo cultured cells holds great promises for the treatment of monogenic diseases as well as cancer. However, carry-over of infectious vector particles has been described to occur upon ex vivo transduction of target cells. This, in turn, may lead to inadvertent spreading of viral particles to off-target cells in vivo, raising concerns for potential adverse effects, such as toxicity of ectopic transgene expression, immunogenicity from in vivo transduced antigen-presenting cells and, possibly, gene transfer to germline cells. Here, we have investigated factors influencing the extent of lentiviral vector (LV) shedding upon ex vivo transduction of human hematopoietic stem and progenitor cells. Our results indicate that, although vector carry-over is detectable when using laboratory-grade vector stocks, the use of clinical-grade vector stocks strongly decreases the extent of inadvertent transduction of secondary targets, likely because of the higher degree of purification. These data provide supportive evidence for the safe use of the LV platform in clinical settings.


Subject(s)
Genetic Therapy , Genetic Vectors , Lentivirus/genetics , Virus Shedding , Antigens, CD34/metabolism , Humans , Lentivirus/physiology , Stem Cells/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...